Matching targets for selective cancer therapy

Drug Discovery Today

Volumn 8, Issue 24, 2003, Pages 1104-1107

  Blagosklonny, Mikhail V ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Cancer biology; Cancer therapy hits; Drug analogs; Drug Discovery; Molecular Medicine; Pharmaceutical Science; Selectivity; Targets; Techniques Methods

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; DOXORUBICIN; HEAT SHOCK PROTEIN 90; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PACLITAXEL; PROTEIN P53; TRANSCRIPTION FACTOR;

BIOAVAILABILITY; BIODIVERSITY; BONE MARROW; CANCER CELL; CANCER THERAPY; CELL CYCLE; CELL KILLING; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; DNA DAMAGE; DRUG DELIVERY SYSTEM; DRUG DESIGN; HUMAN; LETHAL DOSE; LEUKEMIA CELL; MICROTUBULE; MITOSIS; MUTATION; NEOPLASM; PROKARYOTE; PROTEIN EXPRESSION; REVIEW; VALIDATION PROCESS;

EID: 0347480457     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02806-X     Document Type: Short Survey

References (24)

1. Druker B.J. Perspectives on the development of a molecularly targeted agent. Cancer Cell. 1:2002;31-36.
2. Sawyers C.L. FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell. 1:2002;413-415.
3. Rothenberg M.L., et al. Improving the evaluation of new cancer treatments: challenges and opportunities. Nat. Rev. Cancer. 3:2003;303-309.
4. Blagosklonny M.V., Darzynkiewicz Z. Why Iressa failed: toward novel use of kinase inhibitors (Outlook). Cancer Biol. Ther. 2:2003;137-140.
5. Hartwell L.H., et al. Integrating genetic approaches into the discovery of anticancer drugs. Science. 278:1997;1064-1068.
6. Kaelin W.G. Choosing anticancer drug targets in the postgenomic era. J. Clin. Invest. 104:1999;1503-1506.
7. Blagosklonny M.V. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia. 16:2002;455-462.
8. Dixon H., Norbury C.J. Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function. Cell Cycle. 1:2002;362-368.
9. Varshavsky A. Codominant interference, anti-effectors, and multitarget drugs. Proc. Natl. Acad. Sci. U. S. A. 95:1998;2094-2099.
10. Pardee A.B., James L.J. Selective killing of transformed baby hamster kidney (BHK) cells. Proc. Natl. Acad. Sci. U. S. A. 72:1975;4994-4998.
11. Blagosklonny M.V., Darzynkiewicz Z. Cyclotherapy: protection of normal cells and unshielding of cancer cells. Cell Cycle. 1:2002;375-382.
12. Rowinsky E.K., Donehower R.C. Paclitaxel (Taxol). New Engl. J. Med. 332:1995;1004-1014.
13. Abal M., et al. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr. Cancer Drug Targets. 3:2003;193-203.
14. Blagosklonny M.V. Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene. 21:2002;6249-6254.
15. Rahmani M., Grant S. UCN-01 (7-hydroxystauorsporine) blocks PMA-induced maturation and reciprocally promotes apoptosis in human myelomonocytic leukemia cells (U937). Cell Cycle. 1:2002;273-281.
16. Blagosklonny M.V. A new science-business paradigm in anticancer drug development. Trends Biotechnol. 21:2003;103-106.
17. Lane D.P., Hupp T.R. Drug discovery and p53. Drug Discov. Today. 8:2003;347-355.
18. Los M., et al. Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design. Drug Discov. Today. 8:2003;67-77.
19. Zhivotovsky B. More than one road to kill tumor cells: why are they not always successful? Cell Cycle. 2:2003;31-33.
20. Reed J.C. Apoptosis-based therapies. Nat. Rev. Drug Discov. 1:2002;111-121.
21. Reed J.C. Apoptosis-targeted therapies for cancer. Cancer Cell. 3:2003;17-22.
22. Makin G., Dive C. Recent advances in understanding apoptosis: new therapeutic opportunities in cancer chemotherapy. Trends Mol. Med. 9:2003;251-255.
23. Blagosklonny M.V. Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells. Leukemia. 15:2001;936-941.
24. Bunz F., et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 282:1998;1497-1501.